Familial Hypercholesterolemia Multiplex Array by Randox Laboratories Ltd.

Familial Hypercholesterolemia Multiplex Array by Randox Laboratories Ltd. product image
Familial Hypercholesterolemia Multiplex Array
Request Pricing

Receive your quote directly from the manufacturer.

0 Scientists have reviewed this product

Write the First Review

No Reviews

The Familial Hypercholesterolemia (FH) Arrays I & II are rapid, simple and accurate diagnostic tests which enable simultaneous detection of 40 FH-causing mutations (20 mutations per array) within the LDLR, ApoB and PCSK9 genes, which are commonly implicated with FH.

Familial Hypercholesterolemia (FH) is a genetic disorder of lipoprotein metabolism. It is one of the most common autosomal dominant, or inherited, diseases which affect the plasma clearance of LDL-cholesterol (LDL-C), resulting in premature onset of cardiovascular disease (CVD) and a higher mortality risk.

Common genetic defects in FH are mutations in three genes encoding proteins involved in the uptake of LDL-C from the plasma: the low density lipoprotein receptor (LDLR) gene (prevalence of 1 in 500), the apo-lipoprotein B (ApoB) gene (prevalence of 1 in 1000) and the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene (prevalence of less than 1 in 2500).

Patients who have one abnormal gene mutation are known as heterozygous. Heterozygous FH is a common genetic disorder, occurring in 1 person in every 200-500 in most countries. Homozygous FH occurs when the patient has two abnormal gene mutations; however this is much rarer, with an occurrence of 1 in a million.


  • Simultaneous detection of 40 FH-causing mutations within three common genes implicated in FH saves time and cost
  • Detects approximately 80% of disease causing mutations in the UK and Ireland population’
  • Turnaround time of ~3 hours
  • Samples can be assessed in small batches (as few as three samples)
  • Streamlined workflow optimised for the molecular laboratory
  • Single Tube multiplex PCR
  • Added specificity due to combination of stringent PCR and array hybridisation
  • Only 20ng of genomic DNA required
  • Simple report format, with zero post result analysis required